WHO_AAB_TB_2016_84_25
Antiretroviral therapy is recommended for all patients with HIV and drug-resistant TB requiring
second-line antituberculosis drugs irrespective of CD4 cell count, as early as possible (within
the first 8 weeks) following initiation of antituberculosis treatment.